BeOne Medicines Ltd. Quarterly Report for Q2 Ended Jun 30, 2023

Summary

BeiGene, Ltd. (ONC) reported its second quarter 2023 financial results, showcasing significant revenue growth driven by strong performance in its key products, BRUKINSA and tislelizumab. Total revenues surged by 74.3% year-over-year, reaching $595.3 million, primarily due to an 81.8% increase in product revenue to $553.7 million. This growth was fueled by substantial increases in BRUKINSA sales, particularly in the U.S. and Europe, and continued strong sales of tislelizumab in China. Collaboration revenue also saw a modest increase of 12.0%. Despite the top-line growth, the company's operating expenses increased by 17.0%, leading to a continued net loss of $381.1 million for the quarter. However, the net loss narrowed by 32.6% compared to the same period last year, reflecting the significant revenue growth. The company ended the quarter with a strong cash position of $3.4 billion, providing a substantial runway for continued investment in its pipeline and operations.

Key Highlights

• 1Total revenues increased significantly by 74.3% to $595.3 million for Q2 2023 compared to $341.6 million in Q2 2022.
• 2Product revenue grew by 81.8% to $553.7 million, driven by strong sales of BRUKINSA and tislelizumab.
• 3BRUKINSA sales demonstrated exceptional growth, increasing by 139.4% to $308.3 million globally in Q2 2023.
• 4Tislelizumab sales in China also showed robust growth of 42.5%, reaching $149.5 million in Q2 2023.
• 5Operating expenses increased by 17.0% to $914.0 million, primarily due to higher R&D and SG&A costs.
• 6The net loss for Q2 2023 was $381.1 million, a 32.6% improvement compared to a net loss of $565.7 million in Q2 2022.
• 7The company ended the quarter with $3.4 billion in cash, cash equivalents, and restricted cash, indicating a strong liquidity position.

Frequently Asked Questions